Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects

October 18, 2018 By Law Offices of Thomas J. Lamb, P.A.

New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date.

We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as Invokana and other similar diabetes drugs from this October 2, 2018 Medscape Medical Newsreport, “SGLT2 Inhibitor-Amputation Link in Diabetes — Is it Hypovolemia?”:

The mechanism behind the finding of an increased risk of lower-limb amputation in patients taking [Invokana (canagliflozin)] in the Canagliflozin Cardiovascular Assessment Study (CANVAS) has been much debated. Findings from observational trials of [Invokana (canagliflozin)] have conflicted regarding the amputation risk, and the effect hasn’t been seen with other SGLT2 inhibitors.

But, assuming the amputation risk is a class effect, one theory about the mechanism is that the reduction in plasma volume from SGLT2 inhibitors could lead to decreased perfusion, especially in patients who already have reduced lower limb perfusion. “If true, we hypothesized that diuretics would show a similar safety profile,” [explained Ronan Roussel, MD, PhD, chief of the endocrinology, diabetes, and nutrition department at Group Hôpital Bichat, AP-HP, Paris, France]….

“This is a strong signal,” he told Medscape Medical News in an interview, adding that the data suggest diuretics should be used with caution in patients who are at increased risk for amputation, such as those with critical ischemia.

As background, some diabetic patients at the highest risk of amputations are those with peripheral arterial disease or foot ulcers.

Given the increasing medical evidence that lower limb (leg, foot, toes) amputations are a drug-class side effect of SGLT-2 inhibitors, we continue to investigate amputation drug injury cases for patients using Invokana, Farxiga, Jardiance, and similar newer diabetes medications.

[View article at original source]

Invokana / Farxiga / Jardiance

Free Case Evaluation

Strictly Confidential, No Obligation.

Filed Under: Unsafe Drugs Tagged With: Amputations, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, Leg Amputation, Toes Amputation

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.